A B S T R A C T Exposure of fibrinogen receptors by a variety of agonists is a prerequisite for platelet aggregation. Because the synthesis of prostaglandins and thromboxane A2 also occurs during platelet aggregation we wondered whether these agents participate in the exposure of platelet fibrinogen receptors. Therefore, we measured the binding of human 125I-fibrinogen to gel-filtered normal human platelets after prostaglandin and thromboxane synthesis had been inhibited by aspirin or indomethacin. The fibrinogen binding assay was performed at 370C but without stirring to prevent the formation of platelet aggregates. Platelet secretion, measured with [14C]serotonin, did not occur during the procedure. Aspirin or indomethacin inhibited fibrinogen binding stimulated by 10 ,M epinephrine by 53%, and inhibited fibrinogen binding stimulated by 1-2 ,uM ADP by 37.1%. However, ADP at concentrations >2 ,uM returned fibrinogen binding toward control values. Scatchard analysis demonstrated that aspirin decreased the number but not the affinity of the exposed fibrinogen receptors. To determine whether prostaglandins are capable of directly exposing fibrinogen receptors, prostaglandin H2 was used to stimulate platelets in the fibrinogen binding assay. Prostaglandin H2 exposed -54,000 fibrinogen receptors/platelet and corrected the deficit in receptor exposure induced by aspirin. These studies demonstrate that platelet prostaglandins or thromboxane A2 can play a direct role in the exposure of platelet fibrinogen receptors. In addition, they suggest that the synthesis of prostaglandins and thromboxane A2 by stimulated platelets may be all that is required for optimal secondary platelet aggregation.
INTRODUCTION
Platelet aggregation, in vitro and in vivo, occurs in two phases: a primary phase due to direct stimulation by platelet agonists and a secondary phase due to substances produced or released by stimulated platelets (1) . The importance of each of these phases for platelet aggregation depends upon the nature of the platelet agonist. For example, the aggregation response to collagen is entirely dependent upon substances produced or released by the platelet, whereas the aggregation response to thrombin is not (2) . The platelet products that may be involved in secondary platelet aggregation include ADP released from platelet-dense granules (1) , the products of platelet arachidonic acid metabolism (prostaglandin endoperoxides and thromboxane A2) (3), and the recently described platelet activating factor (4) . The relative contribution of these products to secondary platelet aggregation remains an area of controversy. For example, Charo et al. (2) suggested that secondary aggregation may be a direct response to platelet prostaglandins rather than to secreted platelet ADP because they could demonstrate that the onset of secondary platelet aggregation was simultaneous with, and often preceded, the onset of platelet secretion and both could be prevented by inhibition of prostaglandin synthesis. On the other hand, Malmsten et al. (5) have suggested that the aggregation of platelets produced by prostaglandins is mediated by the prostaglandin-stimulated secretion of platelet ADP. Stimulation of platelets by a variety of agonists exposes a limited number of fibrinogen receptors on the platelet surface (6) (7) (8) . Exposure of these receptors is a direct consequence of platelet stimulation and appears to be required for platelet aggregation (6, 9) . Moreover, it is unrelated to platelet shape change (10) and is independent of platelet secretion (6, 7) . Therefore, investigation of the factors involved in fibrinogen receptor exposure permits an examination ofthe events leading to platelet aggregation, isolated from other aspects of platelet function. In this study we Fibrinogen binding to gel-filtered human platelets. The assay used to measure fibrinogen binding by stimulated platelets has been previously described in detail (6) . Briefly, Kabi fibrinogen was further purified by 16% ammonium sulfate fractionation (11) and Sepharose 4B gel filtration chromatography and was radiolabeled with 1251 by the iodine monochloride technique (12) . The specific activity of the radiolabeled fibrinogen was -2 Ci/mmol. Platelet-rich plasma, obtained by differential centrifugation of whole blood anticoagulated with 0.1 vol of 0.13 M sodium citrate, was gel-filtered on Sepharose 2B with Tyrode's buffer (0.14 M NaCl, 0.0027 M KCl, 0.012 M Na HCO3, 0.004 M NaHPO4), pH 7.4, containing 10 mg/ml human albumin and 5.5 mM glucose as the elution buffer (13) . The fibrinogen binding assay was performed by mixing gel-filtered platelets (108/ml) with radiolabeled fibrinogen and 0.5 mM CaCl2. After the platelet suspensions were equilibrated at 37°C, a platelet agonist was added and the incubations were continued at 37°C without stirring. To terminate the incubations, the platelet suspensions were layered on 0.5 ml of a mixture of hi-phenyl silicone and methyl silicone oil (4:1) and the platelets were sedimented through the oil mixture in an Eppendorf centrifuge (model 5412, Brinkman Instruments, Inc., Westbury, N. Y.). After sedimentation, the supernatant buffer and oil were aspirated from the pelleted platelets and the tips of the centrifuge tubes containing the pellets were sliced from the tubes. The tips were then counted for 125I in a Beckman Gamma 8000 counter (Beckman Instruments, Inc., Fullerton, Calif. was 0.24. The area of the developed chromatogram corresponding to PGH2 was scraped and the removed silica gel was extracted with acetone.
When the ability of PGH2 to stimulate fibrinogen binding was measured, an aliquot of the acetone extract was added to a polypropylene tube (Falcon Labware, Div. of BectonDickinson & Co., Oxnard, Calif.), the acetone was evaporated under nitrogen, and a platelet suspension was immediately added. The remainder of the fibrinogen binding assay was performed as described in the previous section.
Studies of platelet aggregation and secretion. Platelet aggregation was studied by the method of Born (16) Statistical analyses for this study were performed with the aid of a Texas Instruments T158 programmable calculator (Texas Instruments, Inc., Digital Systems Div., Dallas, Tex.).
RESULTS
Inhibition of fibrinogen binding by aspirin and indomethacin. The synthesis of prostaglandins and thromboxane A2 is required for the complete aggregation of platelets by epinephrine and ADP (2) . Because the exposure of fibrinogen receptors is a prerequisite for platelet aggregation (6-10), we postulated that prostaglandins or thromboxane A2 should also be responsible for a portion of the fibrinogen binding sites exposed by these agents. To test this hypothesis we prevented platelet prostaglandin synthesis with the fatty acid cyclooxygenase inhibitors aspirin or indomethacin before fibrinogen binding was measured. Platelet-rich plasma was incubated for 20 min at 37°C in the presence and in the absence of 1 mM aspirin.
Essentially complete inactivation of platelet fatty acid cyclooxygenase by aspirin was confirmed by failure of the platelet enzyme to incorporate [3H-acetyl]-' Abbreviation used in this paper: PGH2, prostaglandin H2.
aspirin (19) . The aspirin-treated and control platelets were gel filtered and used immediately for studies of epinephrine-and ADP-stimulated fibrinogen binding. The platelet suspensions were not stirred to prevent the formation of platelet aggregates and the possible induction ofplatelet secretion (20 (21) . Identical results were seen when platelets were obtained from donors who had ingested 600 mg of aspirin on the day before blood donation. Thus, these data are consistent with a direct role for platelet synthesized prostaglandins and/or thromboxane A2 in both epinephrineand ADP-stimulated fibrinogen receptor exposure.
Effect of varying ADP and epinephrine concentrations on fibrinogen binding to aspirin-treated platelets. The extent of aggregation of aspirin-treated platelets stimulated by 10 uM ADP approximated the extent of aggregation of untreated platelets (Fig. 1) . The aspirin-treated platelets did not, however, undergo secretion and the aggregates eventually disaggre- Platelet-rich plasma was incubated at 37°C for 20 min in the presence or absence of 1 mM aspirin. Platelets were then separated from plasma protein by gel filtration on Sepharose 2B, with Tyrode's buffer, pH 7.4, containing 10 mg/ml human albumin and 5.5 mM glucose as the elution buffer. The ability of these platelets to bind labeled fibrinogen in response to ADP or epinephrine was tested as described under Methods. The effect of indomethacin was tested by adding it to control platelet suspensions immediately before platelet stimulation. Results are expressed as the mean±SEM. gated. In contrast, the inhibitory effect of aspirin on the extent of aggregation of epinephrine-stimulated platelets could not be overcome with higher concentrations of epinephrine. In view of these data, we examined the ability of increasing concentrations of epinephrine or ADP to expose fibrinogen receptors on aspirin-treated and control platelets. As illustrated in Fig. 2 , aspirin inhibited epinephrine-stimulated fibrinogen binding at each concentration of epinephrine tested. In contrast, the effect of aspirin on ADPstimulated fibrinogen binding was apparent only at ADP concentrations of c2 ,uM and disappeared as the ADP concentration was increased (Fig. 3) . To insure that the effect of aspirin was not due to its interaction with the fibrinogen binding sites, we measured the affinity of the fibrinogen receptors of aspirintreated and control platelets by Scatchard analysis (22) . As illustrated in Fig. 4 , ADP exposed 47,000 receptors on control platelets but only 29,500 sites on aspirintreated platelets. The Scatchard analysis also demonstrated that ADP exposed a single class of fibrinogen receptors on both aspirin-treated and control platelets with dissociation constants of 0.105 and 0. 4 Scatchard analysis of ADP-stimulated fibrinogen binding to control and aspirin-treated platelets. Aspirintreated and control platelet suspensions were prepared as described in Fig. 1 . Suspensions of 5 x 107 gel-filtered platelets were incubated with increasing concentrations of 125j_ fibrinogen, 0.5 mM CaCl2 and 2 uM ADP for 3 min at 37°C. Specific fibrinogen binding was measured as described in Methods. The data were then analyzed by the method of Scatchard (21) and plotted with the aid of a linear regression analysis. 0, control platelets; 0, aspirin-treated platelets.
receptor exposure rather than on the ability of the exposed receptors to bind fibrinogen.
Exposure of platelet fibrinogen receptors by PGH2. The inhibition of fibrinogen receptor exposure by aspirin and indomethacin is indirect evidence that prostaglandins or thromboxanes participate in this process. To demonstrate directly that prostaglandins are capable of stimulating fibrinogen binding to platelets, the prostaglandin endoperoxide PGH2 was prepared biosynthetically and was used to stimulate unstirred gel-filtered platelets in the presence of radiolabeled fibrinogen and CaCl2. Stimulation of platelets with increasing concentrations of PGH2 resulted in the exposure of a limited number of fibrinogen binding sites (Fig. 5) . Although the sensitivity of platelets from different donors to PGH2 varied, the maximum number of fibrinogen receptors exposed by PGH2 was 54,650 +2,245 (SEM, n = 6), a value not significantly different from the maximum number of fibrinogen receptors exposed by ADP or epinephrine (6) .
Prostaglandin endoperoxides have been shown to initiate platelet secretion (5, 23 (24, 25) . In our assay system, ATP inhibited ADP-stimulated fibrinogen binding with a Ki of 3.8+1.1 ,uM. Moreover, in five experiments, 20 uM ATP inhibited by 90% the fibrinogen binding stimulated by 2 ,M ADP, an ADP concentration that could reasonably result from PGH2-stimulated platelet secretion (26) . In contrast, the fibrinogen binding stimulated by 2-4 ,uM PGH2 was only inhibited by 6% by the same concentration of ATP. Therefore, it is likely that the majority of the fibrinogen binding stimulated by PGH2 is a direct consequence of the interaction of the endoperoxide with the platelet. If aspirin and indoinethacin partially inhibit the response of platelets to ADP and epinephrine by preventing prostaglandin synthesis, then exogenous PGH2 should be able to correct the deficit in fibrinogen receptor exposure produced by these agents. Control and aspirin-treated platelets were stimulated by 10 ,uM epinephrine both in the presence and in the absence of exogenous PGH2. The concentrations of PGH2 used varied from 0.6 to 4.3 ,uM. Aspirin treatment significantly decreased maximal fibrinogen binding from 7.49 ± 1.40 to 3.48+0.64 pmol/108 platelets (P < 0.005, t test for paired samples, n = 5). However, the combination of PGH2 and epinephrine restored fibrinogen binding to 6.88±0.93 pmol/108 platelets, a value not significantly different from the control values. Moreover, the number of fibrinogen receptors exposed by the combination ofepinephrine and PGH2 did not exceed the number of receptors exposed by epinephrine alone.
DISCUSSION
It has been suggested that secondary platelet responses are mediated by the secretion of ADP stored in the platelet-dense granules. This conclusion is based on the failure of collagen, epinephrine, and ADP to elicit secondary aggregation in platelets with an abnormal storage pool of ADP (27) and on the inhibition of secondary aggregation by enzymes that metabolize ADP (28) . Recent data, however, have challenged this conclusion. Storage-pool-deficient platelets may have other abnormalities such as defects in the prostaglandin and thromboxane A2 synthetic pathway (27) . Moreover, the mechanism by which ADP scavengers inhibit platelet aggregation has been questioned. Huang and Detwiler (29) demonstrated that inhibition of thrombin-or epinephrine-stimulated platelet aggregation by creatine phosphate/creatine phosphokinase could be overcome by increased concentrations of thrombin or epinephrine. This suggests that creatine phosphate/ creatine phosphokinase inhibits platelet function by decreasing the sensitivity of platelets to agonist stimulation rather than by catabolizing secreted ADP. In addition, Mustard et al. (30) and Macfarlane and coworkers (31) have suggested that ADP-and epinephrine-stimulated platelet secretion is an artifact of the low calcium concentration that results when citrate is used as an anticoagulant. Thus, despite the effort that has been expended to understand secondary platelet aggregation, a completely satisfactory explanation is not available. In part, this has resulted from difficulties in finding a simple, unambiguous experimental system.
Our fibrinogen binding assay fulfills the requirements for such a system. Fully reactive platelets can be suspended in a defined medium in the absence pf anticoagulants, and the events leading to platelet aggregation can be studied in the absence of platelet secretion. Using this assay, we have demonstrated that the treatment of platelets with the cyclooxygenase inhibitors aspirin and indomethacin decreases the number of fibrinogen receptors exposed by all concentrations of epinephrine and by concentrations of ADP of c2 ,uM. Thus, our data suggest that the prostaglandins and thromboxanes synthesized by stimulated platelets can act in concert with primary agonists to expose fibrinogen receptors. Higher concentrations of ADP can overcome this effect of cyclooxygenase inhibition, which reinforces the concept that several pathways are available to amplify platelet responses.
Other interpretations of our data are possible, however. It Assuming that secretion occurred to the extent of the "4C counting error (2%), the potential concentration of secreted ADP would approximate 50 nM (26) , an ADP concentration insufficient to produce measurable fibrinogen binding (Fig. 3) . Thus, we do not believe that small undetected quantities ofsecreted ADP could account for our data. Another possible explanation for our results is a direct effect of aspirin or indomethacin on the fibrinogen receptor that would decrease its affinity for fibrinogen. But this possibility is not supported by our Scatchard analyses, which demonstrate nearly identical dissociation constants for the fibrinogen receptors on aspirin-treated and control platelets. In addition, the ability of higher ADP concentrations to overcome the aspirin effect demonstrates that a full complement offibrinogen receptors ofnormal affinity can be exposed on aspirin-treated platelets. Finally, aspirin has been shown to modify only a single membrane-associated protein in human platelets (34) .
Our demonstration that exogenous PGH2 stimulates fibrinogen receptor exposure, independent of secreted platelet ADP, is consistent with the ability of the endoperoxide to stimulate platelet aggregation (5, 22) . Furthermore, the ability of PGH2 to restore the response of aspirin-treated platelets to epinephrine supports the suggestion that aspirin affects fibrinogen receptor exposure by inhibiting fatty acid cyclooxygenase. Because the combination of epinephrine and PGH2 (or ADP and PGH2, data not shown) could not expose more fibrinogen binding sites than epinephrine (or ADP) alone, it is likely that the range of44,000-54,000 fibrinogen binding sites per platelet represents the actual number of fibrinogen receptors possessed by human platelets.
In conclusion, we have demonstrated that the products of platelet arachidonic acid metabolism can potentiate the exposure of fibrinogen binding sites by other agonists. Thus, prostaglandin endoperoxides and thromboxane A2, along with secreted ADP, may play a direct role in normal platelet aggregation. Our studies were not intended to address the role of secreted ADP in secondary aggregation. They do, however, suggest that in the presence of a functional arachidonic acid metabolic pathway, the synthesis of prostaglandin endoperoxides and thromboxanes may be all that is required for optimal secondary platelet aggregation.
